Showing results (51-60 of 69) with videos related to
Sort By:
Pageof 7
Journal of Cancer|April 15, 2016
Tyrosine Kinase Inhibitors for the ElderlyWolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Michael Steinheimer, et al.Journal of Cancer|February 10, 2015
Enhancement of Intratumoral Chemotherapy with Cisplatin with or without Microwave Ablation and Lipiodol. Future Concept for Local Treatment in Lung CancerWolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Joshua Stopek, et al.Journal of Cancer|February 27, 2016
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureWolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Georgia Pitsiou, et al.Expert Review of Respiratory Medicine|September 30, 2021
Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot studyPaul Zarogoulidis, Dimitris Petridis, Haidong Huang, et al.Lung Cancer (Amsterdam, Netherlands)|February 14, 2024
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trialLuis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, et al.Expert Review of Respiratory Medicine|December 4, 2020
Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combinationPaul Zarogoulidis, Vagelis Christakidis, Dimitris Petridis, et al.Journal of Cancer|January 19, 2018
Interferon-γ and Colorectal Cancer: an up-to dateChristoforos Kosmidis, Konstantinos Sapalidis, Triantafyllia Koletsa, et al.Journal of Cancer|June 22, 2026
CellVizio® System for Mesothorax Lymphadenopathy Rapid on Site, 18G needle: Pros and ConsPaul Zarogoulidis, Wolfgang Hofenforst-Schwidt, Haidong Huang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.Therapeutic Advances in Medical Oncology|September 15, 2022
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre studyFoteinos-Ioannis Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, et al.Pageof 7